SEC Form SCHEDULE 13D filed by Atlantic International Corp.
$ATLN
Biotechnology: Laboratory Analytical Instruments
Industrials
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
|
Atlantic International Corp. (Name of Issuer) |
Common Stock, Par Value $0.00001 per share (Title of Class of Securities) |
048592109 (CUSIP Number) |
Elliot H. Lutzker 605 Third Avenue, New York, NY, 10158 212-557-7200 Davidoff Hutcher & Citron LLP 605 Third Avenue, New York, NY, 10158 212-557-7200 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
01/02/2025 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. | 048592109 |
| 1 |
Name of reporting person
Jeffrey Jagid | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
 (a)
(b)
| ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
OO | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
UNITED STATES
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
6,621,025.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
10.6 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock, Par Value $0.00001 per share |
| (b) | Name of Issuer:
Atlantic International Corp. |
| (c) | Address of Issuer's Principal Executive Offices:
270 Sylvan Avenue, Suite 2230, Englewood Cliffs,
NEW JERSEY
, 07632. |
| Item 2. | Identity and Background |
| (a) | Jeffrey Jagid |
| (b) | 270 Sylvan Avenue, Suite 2230, Englewood Cliffs, New Jersey 07632. |
| (c) | CEO and Director, Atlantic International Corp., 270 Sylvan Avenue, Suite 2230, Englewood Cliffs, New Jersey 07632. |
| (d) | No criminal proceedings to be disclosed |
| (e) | No civil proceedings to be disclosed |
| (f) | United States |
| Item 3. | Source and Amount of Funds or Other Consideration |
See Item 5(c) below. | |
| Item 4. | Purpose of Transaction |
There are no plans or proposals which the reporting person has which may result in any of the matters listed. | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | 6,621,025 (10.6%) shares based on 62,241,187 shares issued and outstanding as of January 7, 2025. |
| (b) | Sole voting power and disposition power - 6,621,025 shares. |
| (c) | Pursuant to the terms and conditions of an Executive Employment Agreement dated June 18, 2024, by and between Mr. Jagid and Atlantic International Corp., Mr. Jagid received 3,735,169 shares of Common Stock of the Issuer, upon the June 18, 2024 merger with SeqLL Inc., which changed its name to Atlantic International Corp. On January 2, 2025, he was awarded restricted stock units ("RSUs") under his employment agreement to purchase 2,885,856 shares of common Stock, which RSUs were exercised. |
| (d) | No person has the right to receive, or the power to direct the receipt of dividends from, or proceeds from, the sale of such securities. |
| (e) | Not applicable. |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
None | |
| Item 7. | Material to be Filed as Exhibits. |
None |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|